AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29743226 — intervention group
Group type: EXPERIMENTAL
Intervention: 5As Team intervention
Number of subjects: 29
Study 29743836 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg BID
Number of subjects: 121
Study 29743836 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg BID
Number of subjects: 121
Study 29743836 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 121
Study 29744054 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing audio
Number of subjects: 38
Study 29744054 — intervention group
Group type: COMPARATOR
Intervention: Neutral stimulus (control)
Number of subjects: 38
Study 29744332 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29745457 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir
Number of subjects: 33
Study 29745457 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 33
Study 29745457 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled population
Number of subjects: 33
Study 29745457 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Framingham score
Number of subjects: 33
Study 29745457 — intervention group
Group type: EXPERIMENTAL
Intervention: AIx@75
Number of subjects: 33
Study 29745476 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit plaque rupture (CPR)
Number of subjects: 209
Study 29745476 — intervention group
Group type: EXPERIMENTAL
Intervention: Necrotic core with macrophage infiltrations (NCMI)
Number of subjects: 209
Study 29745476 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy with prasugrel/ticagrelor at discharge
Number of subjects: 209
Study 29745476 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up duration
Number of subjects: 209
Study 29746485 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 100
Study 29746485 — intervention group
Group type: COMPARATOR
Intervention: NNRTI/PI-based ART
Number of subjects: 100
Study 29746631 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically attended influenza (CFRMA) during the pandemic period (2009-2011)
Number of subjects: 843
Study 29746631 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization rate of pH1N1-positive outpatients
Number of subjects: 843
Study 29746631 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rate of pH1N1-positive inpatients
Number of subjects: 843
Study 29746631 — intervention group
Group type: EXPERIMENTAL
Intervention: CFRAR for the 2009 pandemic
Number of subjects: 843
Study 29746631 — intervention group
Group type: EXPERIMENTAL
Intervention: CFRMA for young adults during the post-pandemic period
Number of subjects: 843
Study 29746631 — intervention group
Group type: EXPERIMENTAL
Intervention: CFR for influenza-negative patients
Number of subjects: 843
Study 29746639 — intervention group
Group type: COMPARATOR
Intervention: BCAA diet (1.03 g · kg-1 · d-1)
Number of subjects: 5
Study 29746639 — intervention group
Group type: COMPARATOR
Intervention: EAA diet (1.23 g · kg-1 · d-1)
Number of subjects: 5
Study 29746639 — intervention group
Group type: COMPARATOR
Intervention: SUF diet (1.75 g · kg-1 · d-1)
Number of subjects: 5
Study 29746639 — intervention group
Group type: COMPARATOR
Intervention: NEAA diet (1.75 g · kg-1 · d-1)
Number of subjects: 5
Study 29746639 — intervention group
Group type: EXPERIMENTAL
Intervention: BASE diet (0.8 g · kg-1 · d-1)
Number of subjects: 5
Study 29746650 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement
Number of subjects: 351
Study 29747074 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day of zinc from day +5 to day +100 after transplant
Number of subjects: 18
Study 29747074 — intervention group
Group type: COMPARATOR
Intervention: Standard antimicrobial prophylaxis
Number of subjects: 18
Study 29747644 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-based tools for insurance assistance
Number of subjects: 15024
Study 29747670 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiedu Tongluo granules (JDTLG) with conventional treatment
Number of subjects: 80
Study 29747670 — intervention group
Group type: COMPARATOR
Intervention: Placebo with conventional treatment
Number of subjects: 80
Study 29747670 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiedu Tongluo granules (JDTLG)
Number of subjects: 80
Study 29747670 — intervention group
Group type: COMPARATOR
Intervention: Jiedu Tongluo granules (JDTLG) and placebo
Number of subjects: 80
Study 29747700 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol (2 g, twice per day) for three months followed by myo-inositol plus alpha-lactalbumin (50 mg, twice per day) for three months
Number of subjects: 37
Study 29747700 — intervention group
Group type: COMPARATOR
Intervention: Myo-inositol (2 g, twice per day) for three months
Number of subjects: 37
Study 29747700 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol plus alpha-lactalbumin (50 mg, twice per day)
Number of subjects: 37
Study 29747838 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose Ferric Carboxymaltose
Number of subjects: 0
Study 29747915 — intervention group
Group type: EXPERIMENTAL
Intervention: Third universal definition of PCI-related myocardial infarction (MI)
Number of subjects: 13038
Study 29747915 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAI criteria for PCI-related MI
Number of subjects: 13038
Study 29747915 — intervention group
Group type: COMPARATOR
Intervention: Local investigator detection of angiographic complications
Number of subjects: 13038
Study 29748148 — intervention group
Group type: EXPERIMENTAL
Intervention: LPL-FCS individuals
Number of subjects: 52
Study 29748148 — intervention group
Group type: COMPARATOR
Intervention: non-LPL-FCS individuals
Number of subjects: 52
Study 29748160 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity tracking using Fitbit Alta HR and a mobile phone app designed for the study.
Number of subjects: 50
Study 29748160 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity tracking with weekly review of self-reports and activity information.
Number of subjects: 50
Study 29748160 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity tracking and self-reporting with weekly review.
Number of subjects: 50
Study 29748219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1278
Study 29748344 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection and abstraction of patient characteristics, diagnostic testing, treatments, and in-hospital outcomes.
Number of subjects: 10000
Study 29748435 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-treatment PET (negative Deauville 1-3)
Number of subjects: 93
Study 29748435 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-treatment PET (positive Deauville 4-5)
Number of subjects: 93
Study 29748443 — intervention group
Group type: EXPERIMENTAL
Intervention: coltuximab ravtansine
Number of subjects: 61
Study 29748444 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine (90 mg/m²) plus Rituximab
Number of subjects: 100
Study 29748444 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 100
Study 29748602 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant clinical trials (NCT02876107 and NCT03101748)
Number of subjects: 0
Study 29748650 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan medical professionals
Number of subjects: 198
Study 29748650 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian medical professionals
Number of subjects: 198
Study 29748650 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnivore medical professionals
Number of subjects: 198
Study 29748650 — intervention group
Group type: COMPARATOR
Intervention: Omnivores
Number of subjects: 198
Study 29748650 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegans and vegetarians
Number of subjects: 198
Study 29748650 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegans
Number of subjects: 198
Study 29748847 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib 600 mg twice daily (BID)
Number of subjects: 225
Study 29748847 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib 600 mg BID
Number of subjects: 225
Study 29749274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle-tracking apps
Number of subjects: 949
Study 29749274 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard days method
Number of subjects: 949
Study 29749274 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm method
Number of subjects: 949
Study 29749274 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative rhythm method
Number of subjects: 949
Study 29749274 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple calendar method
Number of subjects: 949
Study 29749279 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioligands for imaging TSPO
Number of subjects: 0
Study 29749403 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab-bendamustine (G-B)
Number of subjects: 158
Study 29749945 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing (ATP) only
Number of subjects: 1670
Study 29749945 — intervention group
Group type: COMPARATOR
Intervention: At least 1 shock
Number of subjects: 1670
Study 29749945 — intervention group
Group type: COMPARATOR
Intervention: ATP only
Number of subjects: 1670
Study 29749945 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 1670
Study 29750067 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vitamin-K-antagonist oral anticoagulant (NOAC) treatment
Number of subjects: 37439
Study 29750067 — intervention group
Group type: COMPARATOR
Intervention: Vitamin-K-antagonist (VKA) treatment
Number of subjects: 37439
Study 29750396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel at a starting dose of 20 mg/m², escalated to a maximum tolerated dose (MTD) of 30 mg/m².
Number of subjects: 23
Study 29750396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel at a dose of 35 mg/m².
Number of subjects: 23
Study 29750396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (general safety profile).
Number of subjects: 23
Study 29750416 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 419
Study 29750416 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of 25(OH)D
Number of subjects: 419
Study 29750416 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2R1 rs12794714
Number of subjects: 419
Study 29750416 — intervention group
Group type: EXPERIMENTAL
Intervention: C10orf88 rs6599638
Number of subjects: 419
Study 29750698 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postoperative copeptin concentrations (0 h)
Number of subjects: 30
Study 29750698 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative copeptin concentrations
Number of subjects: 30
Study 29750699 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop-assisted goal-directed fluid therapy (GDFT) with a baseline crystalloid infusion of 3 ml/kg/h and additional 100 ml fluid boluses of crystalloid or colloid.
Number of subjects: 208
Study 29750699 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop-assisted goal-directed fluid therapy (GDFT)
Number of subjects: 208
Study 29750699 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (non-GDFT patients)
Number of subjects: 208
Study 29750747 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine at a dose of 50 mg/m/d for 5 days
Number of subjects: 15
Study 29750747 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine
Number of subjects: 15
Study 29750766 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed infants
Number of subjects: 1000
Study 29750766 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal education <12 years
Number of subjects: 1000
Study 29750766 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal viral load >1,000,000 copies/mL at delivery
Number of subjects: 1000
Study 29750766 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall infant mortality rate
Number of subjects: 1000
Study 29750766 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant mortality rate in Brazil
Number of subjects: 1000
Study 29750766 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant mortality rate in South Africa
Number of subjects: 1000
Study 29750766 — intervention group
Group type: EXPERIMENTAL
Intervention: Undernutrition and stunting at 1 month of age
Number of subjects: 1000
Study 29750766 — intervention group
Group type: COMPARATOR
Intervention: Infant mortality likelihood in South Africa vs Brazil
Number of subjects: 1000
Study 29750766 — intervention group
Group type: COMPARATOR
Intervention: High maternal viral load
Number of subjects: 1000
Study 29750766 — intervention group
Group type: COMPARATOR
Intervention: Birth weight-for-age Z score ≤-2
Number of subjects: 1000
Study 29750955 — intervention group
Group type: EXPERIMENTAL
Intervention: Myomectomy (46% of all procedures, with laparoscopic or robotic myomectomy comprising 19% of all procedures)
Number of subjects: 2031
Study 29750955 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy (38% of all procedures)
Number of subjects: 2031
Study 29750983 — intervention group
Group type: EXPERIMENTAL
Intervention: SIC-8000
Number of subjects: 211
Study 29750983 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 211
Study 29751110 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG reactivity to eye opening in patients who later developed pain
Number of subjects: 41
Study 29751110 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG reactivity to eye opening in patients with existing pain
Number of subjects: 41
Study 29751110 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha band power at BA7 in patients with or later developing pain
Number of subjects: 41
Study 29751110 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant alpha frequency and beta band power at BA7 in all SCI groups
Number of subjects: 41
Study 29751110 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG reactivity to eye opening and reduced spontaneous and induced alpha activity over the parietal cortex
Number of subjects: 41
Study 29751154 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 90
Study 29751154 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapies
Number of subjects: 90
Study 29751168 — intervention group
Group type: EXPERIMENTAL
Intervention: Hoarding Disorder (HD) group
Number of subjects: 83
Study 29751168 — intervention group
Group type: COMPARATOR
Intervention: Healthy Control (HC) group
Number of subjects: 83
Study 29751507 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation pre-RT
Number of subjects: 70
Study 29751507 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation post-RT
Number of subjects: 70
Study 29751507 — intervention group
Group type: COMPARATOR
Intervention: Placebo post-RT
Number of subjects: 70
Study 29751792 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine-based chemotherapy
Number of subjects: 6
Study 29751980 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29752199 — intervention group
Group type: EXPERIMENTAL
Intervention: R-GemOx regimen (rituximab 375 mg/m2, gemcitabine, and oxaliplatin) administered intravenously as first-line treatment.
Number of subjects: 60
Study 29752199 — intervention group
Group type: EXPERIMENTAL
Intervention: R-GemOx regimen (rituximab 375 mg/m2, gemcitabine, and oxaliplatin) administered intravenously.
Number of subjects: 60
Study 29752388 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI plus optimal medical therapy (OMT)
Number of subjects: 2287
Study 29752388 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 2287
Study 29753353 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT-facilitated care (TC)
Number of subjects: 1406
Study 29753517 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal fluids approach (50 to 75 mL/kg during the first 6 hours)
Number of subjects: 0
Study 29753517 — intervention group
Group type: COMPARATOR
Intervention: Restrictive fluids approach (≤30 mL/kg)
Number of subjects: 0
Study 29753544 — intervention group
Group type: EXPERIMENTAL
Intervention: Late diagnosis (diagnosis at or after age 13 years)
Number of subjects: 110
Study 29753544 — intervention group
Group type: COMPARATOR
Intervention: Early diagnosis (diagnosis before age 13 years)
Number of subjects: 110
Study 29753733 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography (CTA)
Number of subjects: 440
Study 29754400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadherence to physical activity
Number of subjects: 1397
Study 29754400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadherence to sun protection
Number of subjects: 1397
Study 29754400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadherence to diet recommendations
Number of subjects: 1397
Study 29754400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadherence to alcohol consumption guidelines
Number of subjects: 1397
Study 29754400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadherence to smoking cessation
Number of subjects: 1397
Study 29754400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadherence to follow-up visits
Number of subjects: 1397
Study 29754500 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare primary headaches (Chapter 3 and Chapter 4 of the International Classification of Headache Disorders 3rd edition)
Number of subjects: 20883
Study 29754500 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster headaches (most frequently diagnosed rare headaches)
Number of subjects: 20883
Study 29754661 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 2200
Study 29754661 — intervention group
Group type: COMPARATOR
Intervention: State-of-the-art rate or rhythm control drug therapy
Number of subjects: 2200
Study 29754670 — intervention group
Group type: EXPERIMENTAL
Intervention: PACT-HF transitional care model including self-care education, multidisciplinary care, early follow-up, post-discharge nurse-led home visits, and outpatient care in Heart Function clinics.
Number of subjects: 3200
Study 29755397 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 29755591 — intervention group
Group type: EXPERIMENTAL
Intervention: Turnip rapeseed oil
Number of subjects: 37
Study 29755591 — intervention group
Group type: COMPARATOR
Intervention: Butter
Number of subjects: 37
Study 29755707 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral colistin for 14 days
Number of subjects: 0
Study 29755707 — intervention group
Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 0
Study 29756206 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pimasertib (once daily for 5 days on/2 days off or twice daily continuously) combined with weekly gemcitabine (1,000 mg/m2)
Number of subjects: 53
Study 29756206 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pimasertib
Number of subjects: 53
Study 29756206 — intervention group
Group type: COMPARATOR
Intervention: Weekly gemcitabine (1,000 mg/m2)
Number of subjects: 53
Study 29756211 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) for appropriate candidates
Number of subjects: 471
Study 29756211 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) for uncertain candidates
Number of subjects: 471
Study 29756211 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sinus surgery (ESS) for inappropriate candidates
Number of subjects: 471
Study 29756531 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Malaria Vaccine (GSK/PATH-MVI RTS,S)
Number of subjects: 52
Study 29756750 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil IV infusion of 0.005 µg/kg/min
Number of subjects: 40
Study 29756750 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil IV infusion of 0.05 µg/kg/min
Number of subjects: 40
Study 29756750 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil IV infusion of 0.1 µg/kg/min
Number of subjects: 40
Study 29756750 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil IV infusion of 0.15 µg/kg/min
Number of subjects: 40
Study 29756750 — intervention group
Group type: EXPERIMENTAL
Intervention: NOL monitoring
Number of subjects: 40
Study 29757399 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEAS ≥40 µg/dL
Number of subjects: 432
Study 29757399 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEAS
Number of subjects: 432
Study 29758112 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 0
Study 29758112 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA)
Number of subjects: 0
Study 29758112 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapies targeting FXR, TGR5, PPAR, PXR
Number of subjects: 0
Study 29758112 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29758172 — intervention group
Group type: EXPERIMENTAL
Intervention: E-consent process
Number of subjects: 86
Study 29758405 — intervention group
Group type: EXPERIMENTAL
Intervention: AV algorithm pacing
Number of subjects: 64
Study 29758405 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 64
Study 29759075 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP patients (non-severe and severe)
Number of subjects: 175
Study 29759075 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolite panel (lactate, sphinganine, DHEA-S)
Number of subjects: 175
Study 29759075 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 175
Study 29759110 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional telemonitoring, nutrition education, and follow-up by a nurse for 6 months
Number of subjects: 214
Study 29759500 — intervention group
Group type: EXPERIMENTAL
Intervention: TYRX Antibacterial Envelope
Number of subjects: 1129
Study 29759500 — intervention group
Group type: EXPERIMENTAL
Intervention: TYRX Antibacterial Envelope (CRT cohort)
Number of subjects: 1129
Study 29759500 — intervention group
Group type: EXPERIMENTAL
Intervention: TYRX Antibacterial Envelope (ICD group)
Number of subjects: 1129
Study 29759500 — intervention group
Group type: COMPARATOR
Intervention: Control (site-matched and comorbidity-matched)
Number of subjects: 1129
Study 29759500 — intervention group
Group type: COMPARATOR
Intervention: Control (published benchmark)
Number of subjects: 1129